Equity Overview
Price & Market Data
Price: $14.23
Daily Change: +$0.48 / 3.37%
Daily Range: $13.75 - $14.65
Market Cap: $308,623,072
Daily Volume: 14,161
Performance Metrics
1 Week: 22.67%
1 Month: 6.75%
3 Months: 85.77%
6 Months: -5.80%
1 Year: -5.80%
YTD: -0.56%
Company Details
Employees: 22
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.